STOCK TITAN

GETY insider sale notice: 14,491 shares via Morgan Stanley disclosed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Getty Images Holdings, Inc. (GETY) filed a Rule 144 notice disclosing a proposed sale of 14,491 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $28,257.45. The filing lists 414,811,306 shares outstanding and an approximate sale date of 09/15/2025. The securities were acquired as Restricted Stock Units: 12,574 units on 03/20/2024 and 1,917 units on 06/20/2025. Recent reported sales in the past three months include 10b5-1 transactions on 09/12/2025 and earlier sales on 06/25/2025, with gross proceeds shown per seller. The filer certifies no undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine insider disclosure showing planned sale of a small block of shares from RSUs; limited market impact.

The Form 144 reports a proposed sale of 14,491 shares valued at $28,257.45 against an outstanding base of 414,811,306 shares, indicating this is a very small dilution or market-immediate supply event. The shares were received as Restricted Stock Units in 2024 and 2025, which suggests standard executive compensation vesting rather than a liquidity-driven sale of long-held shares. Recent 10b5-1 sales by named individuals provide additional context that insiders are executing pre-established plans. Overall, the disclosure is informative but unlikely to be material to Getty Images' valuation.

TL;DR: Filing appears procedurally complete and includes 10b5-1 sale notices; no regulatory red flags apparent in the document.

The notice names Morgan Stanley Smith Barney as broker and details acquisition dates and types (Restricted Stock Units), which aligns with required Rule 144 disclosures. The inclusion of recent 10b5-1 sales and the signer’s representation that no undisclosed material adverse information exists are standard compliance elements. There is no indication of misstated consideration or unusual payment arrangements. From a compliance perspective, the filing satisfies disclosure expectations for an insider sale.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Getty Images' Form 144 (GETY) disclose about the proposed sale?

The filing discloses a proposed sale of 14,491 common shares with an aggregate market value of $28,257.45, approximate sale date 09/15/2025, via Morgan Stanley Smith Barney.

How many shares outstanding does the Form 144 report for GETY?

The filing reports 414,811,306 shares outstanding.

When and how were the shares to be sold acquired according to the filing?

The shares were acquired as Restricted Stock Units: 12,574 on 03/20/2024 and 1,917 on 06/20/2025.

Were there any recent insider sales disclosed in the filing?

Yes. The filing lists 10b5-1 sales on 09/12/2025 (e.g., 31,078 and 26,913 shares) and earlier sales on 06/25/2025 (2,610 and 4,836 shares) with gross proceeds shown per sale.

Does the filer assert they possess any undisclosed material information?

The filer represents by signing the notice that they do not know any material adverse information